Mandate

Vinge advises ABG Sundal Collier, Carnegie and Nordea in connection with the listing of RevolutionRace on Nasdaq Stockholm

Vinge advises ABG Sundal Collier, Carnegie and Nordea in connection with the listing of RVRC Holding AB (publ) on Nasdaq Stockholm.

The offering price was SEK 75 per share, corresponding to a market value of for all outstanding shares in RevolutionRace of approximately SEK 8,469 million. Provided that the over-allotment option is exercised in full, the offering will comprise 37,784,094 shares or approximately SEK 2,834 million.

RevolutionRace offers high quality functional clothing for people with an active lifestyle. The company was founded in 2013 by Pernilla Nyrensten, CEO and Niclas Nyrensten, Creative Director. Since its inception, the founders have had the goal of creating multifunctional clothing with great fit, in the highest quality and at reasonable prices under the tag line "Nature is our playground". By selling clothes online, directly to consumers without unnecessary intermediaries, RevolutionRace can offer products that have an unbeatable value in terms of price, quality and design. Together with its customers, the company has grown rapidly and is selling its products to more than 35 countries.

Vinge’s team consisted of David Andersson, Rikard Lindahl and Anders Sundin Lundberg.

 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025